From: A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
 | LY2603618/gemcitabine | Gemcitabine |
---|---|---|
(n = 65) | (n = 34) | |
Progression-free survival, mos. | Â | Â |
 Median (range) | 3.5 (0–15.9) | 5.6 (0–17.4) |
Duration of response, mos. | Â | Â |
Median (range) | 3.5 (1.5–14.1) | 6.0 (3.7–6.8) |
Best Overall Response, n (%; 95% CI) | ||
 CR | 0 | 0 |
 PR | 14 (21.5%; 12.3–33.5) | 3 (8.8%; 1.9–23.7) |
 SD | 22 (33.8%; 22.6–46.6) | 19 (55.9%; 37.9–72.8) |
Clinical Benefit Rate, n (%; 95% CI) | 36 (55.4%; 42.5–67.7) | 22 (64.7%; 46.5–80.3) |